炎症性肠病患者与健康对照者肠道菌群差异的系统综述
该研究通过MEDLINE、EMBASE等数据库检索至2018年4月2日,纳入48项比较炎症性肠病患者与健康对照者肠道菌群的研究。多数研究针对成人克罗恩病或溃疡性结肠炎,部分菌属丰度存在差异,但结果不一致,菌群多样性或降低或无差异。
要点
- 部分菌属在炎症性肠病患者中丰度改变,但研究间结果不一致。
- 菌群多样性在患者与对照间或降低或无差异。
- 多数研究未充分匹配性别和年龄,方法异质性大。
核心结论
- 部分细菌丰度在炎症性肠病患者与对照间存在差异,但因研究结果和方法不一致无法得出结论。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE、Cochrane数据库至2018年4月2日,纳入48项研究(来自45篇文献)。
主要发现
- Christensenellaceae和Coriobacteriaceae在全部3项研究中均减少,Faecalibacterium prausnitzii在11项研究中的6项减少。
- 克罗恩病患者中Actinomyces、Veillonella和Escherichia coli各在2项研究中增加。
- 溃疡性结肠炎患者中Eubacterium rectale和Akkermansia在全部3项研究中减少,E coli在9项研究中的4项增加。
- 菌群多样性在患者与对照间或降低或无差异。
关键数值与推荐
- Christensenellaceae和Coriobacteriaceae减少:基于各3项研究。
- Faecalibacterium prausnitzii减少:基于11项研究中的6项。
- Eubacterium rectale和Akkermansia减少:基于各3项研究。
- E coli增加:克罗恩病基于2项研究,溃疡性结肠炎基于9项研究中的4项。
临床怎么用
- 目前证据尚不足以支持特定菌属作为炎症性肠病诊断或治疗的靶点,临床决策需谨慎。
局限性
- 研究间结果和方法不一致,多数研究未报告性别和年龄可比性。
- 需要更大规模、方法更优的研究评估微生物种群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Altering the intestinal microbiota has been proposed as a treatment for inflammatory bowel diseases (IBDs), but there are no established associations between specific microbes and IBD. We performed a systematic review to identify frequent associations. METHODS: We searched the MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials databases, through April 2, 2018 for studies that compared intestinal microbiota (from fecal or colonic or ileal tissue samples) among patients (adult or pediatric) with IBD vs healthy individuals (controls). The primary outcome was difference in specific taxa in fecal or intestinal tissue samples from patients with IBD vs controls. We used the Newcastle-Ottawa scale to assess the quality of studies included in the review. RESULTS: We identified 2631 citations; 48 studies from 45 articles were included in the analysis. Most studies evaluated adults with Crohn's disease or ulcerative colitis. All 3 studies of Christensenellaceae and Coriobacteriaceae and 6 of 11 studies of Faecalibacterium prausnitzii reported a decreased amount of those organisms compared with controls, whereas 2 studies each of Actinomyces, Veillonella, and Escherichia coli revealed an increased amount in patients with Crohn's disease. For patients with ulcerative colitis, Eubacterium rectale and Akkermansia were decreased in all 3 studies, whereas E coli was increased in 4 of 9 studies. The microbiota diversity was either decreased or not different in patients with IBD vs controls. Fewer than 50% of the studies stated comparable sexes and ages of cases and controls. CONCLUSIONS: In a systematic review, we found evidence for differences in abundances of some bacteria in patients with IBD vs controls, but we cannot make conclusions due to inconsistent results and methods among studies. Further large-scale studies, with better methods of assessing microbe populations, are needed.
引用
- Pittayanon R, Lau JT, Leontiadis GI, et al. Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology. 2019. PMID: 31812509. doi:10.1053/j.gastro.2019.11.294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。